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Abstract
The purpose of this project was to increase adherence to the U.S. Preventive Services Task Force
and National Comprehensive Cancer Network guidelines for breast cancer screening and genetic
testing. Screening for breast cancer risk factors including genetic testing helps reduce the
incidence of breast cancer. A protocol was developed based on national clinical guidelines to
increase screening and genetic testing for breast cancer. Provider responsibilities included
screening all patients 18 and older for risks factors of breast cancer, referring patients with a
significant risk based on the screening for genetic testing and providing referrals for genetic
counseling once genetic testing was complete. One hundred fifty-four (47%) of the patients
meeting inclusion criteria were screened with 25 (19%) having a positive screen. Fourteen (56%)
patients with a positive screen opted for genetic testing, one patient was confirmed having a
clinically significant mutation in the BRCA1 gene. One of the fourteen patients was identified as
having a 35% remaining lifetime breast cancer risk and one patient was identified as having a
non-clinically significant mutated gene. Three patients were referred to genetic counseling. One
patient followed up with a genetic counselor. Ten (25%) patients meeting genetic testing criteria
declined testing. BRCA gene mutations are associated with breast cancer as well as ovarian,
melanoma, pancreatic, and prostate cancers. Providers and patients need additional education on
the benefits of genetic testing in identifying patients at risk for breast cancer. Early detection and
implementation of preventive measures can help reduce morbidity and mortality rates.
Keywords: breast cancer screening, genetic testing, BRCA mutation
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Genetic Screening for Breast Cancer in Primary Care Setting
It is estimated that there will be 2,088,849 new cases of breast cancer worldwide in 2018
with a mortality rate of 626,679 or 30% (Bray et al., 2018). Ten percent of these breast cancers
likely resulted from hereditary causes, with more than 50% of genetic mutations occurring in the
breast cancer gene one (BRCA1) and breast cancer gene two (BRCA2) (Bray et al., 2018). Up to
80% of people at risk of getting breast cancer have not received genetic testing, mainly because
they do not meet the breast screening guidelines that were established more than 20 years ago
(Beitsch et al., 2018). The practice guidelines have neither been updated to reflect advances in
genetic testing that can provide clinicians with more information regarding cancer risks nor have
the practice guidelines been updated to reflect the need to screen men for breast cancer. Due to
the high mortality rate associated with breast cancer in both women and men, an intervention
implementing an evidence-based practice screening tool in a primary care clinic was chosen for
this project with the expectation that it would increase the number of people being screened.
Screening more patients would help identify those individuals who might be at high risk for
mutations in the BRCA genes (Bray et al., 2018). Genetic testing provides confirmation of
mutated genes that may potentially contribute to the development of cancer, allowing individuals
with these mutations to implement preventive measures such as lifestyle changes or starting
mammograms earlier and more frequently (Keating & Pace, 2018). On average, women living in
the United States have a 12.4% or a 1 in 8 risk of being diagnosed with breast cancer in their
lifetime (DeSantis, Ma, Sauer, Newman, & Jemal, 2017). Mutations in the BRCA genes that
cause breast cancer in women have also been linked to causing breast and prostate cancer in men
(Bray et al., 2018). A recent genomic screening in 2018 of 50,000 people showed that over 80%
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of individuals did not know they had identifiable genetic risks (Beitsch et al., 2018). Although
mammograms and self-breast exams have been included in recommended screening guidelines,
these screening guidelines do not apply to men and recent studies have shown that these
screening methods may be contraindicated to use in the screening of young women (Keating &
Pace, 2018). Furthermore, surveys have shown that majority of primary care providers do not
routinely screen for breast cancer using either the old or current screening guidelines (Gornick et
al., 2018).
Statement of the Problem
Breast cancer is the most common cancer diagnosed among women in the United States
and is the second leading cause of cancer death in women (DeSantis et al., 2017). Approximately
41,000 people passed away from breast cancer in 2017 (DeSantis et al., 2017). It is estimated that
in 2018, there were 266,120 new cases of women diagnosed with breast cancer, along with 2,550
new cases in men in the United States alone (American Cancer Society, 2018). These are large
numbers that could be reduced significantly with preventive measures including performing
early screening for genetic testing (DeSantis et al., 2017). Between 250,000 and 415,000 men
and women are at a high risk of being diagnosed with breast cancer that is potentially
preventable with early detection (King, Levy-Lahand, & Lahad, 2014). Data from the National
Cancer Institute (2012) shows the 10 year frequency and probability of developing breast cancer
among U.S. women by age and over the course of a lifetime. Table 1 summarizes these findings.
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Table 1
Age Specific Probability of Developing Breast Cancer
Age

10 Year Risk

10 Year Probability

20

1 in 1,567

0.1%

30

1 in 227

0.44%

40

1 in 68

1.47%

50

1 in 42

2.38%

60

1 in 28

3.56%

70

1 in 26

3.82%

Lifetime risk

1 in 8

12.4%

BRCA1 and BRCA2 mutations are equally common in men as in women and are
inherited equally from their mothers and fathers (King et al., 2014). For men, the risk of being
diagnosed with breast cancer is about 1 in 833, with an estimated 480 deaths annually (American
Cancer Society, 2018). Although these numbers are far less dramatic than for women, the
mortality rate is significant at a rate of approximately 58%. This may be attributed to the fact that
there are no breast cancer screening guidelines for men, thus by the time men are diagnosed with
breast cancer, there is a high probability of metastasis of more advanced cancers which usually
results in a poorer prognosis (American Cancer Society, 2018). In general, the survival rates
improve if breast cancer is detected early (American Cancer Society, 2018). Figure 1 shows 5
year survival rates among men correlated to the diagnosed stage of cancer as noted by the
American Cancer Society (2018).
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Figure 1. Male breast cancer 5-year survival rates by stage of cancer.

Studies have shown harm from over diagnosing breast cancers related to false-positives
from mammography (Keating & Pace, 2018). Evidence from several randomized clinical trials
suggest that 19% of women diagnosed by mammogram screenings are considered over
diagnosed, subjecting women to treatment without any benefit (Keating & Pace, 2018). Over the
past 9 years, there have been many changes in the recommendations for breast cancer screenings
(Keating & Pace, 2018). In 2009, the U.S. Preventive Services Task Force (USPSTF) recognized
evidence of harm from mammograms such as unnecessary surgeries, medications, further
imaging and biopsies which has resulted in revisions to the taskforce’s recommendations that
now include biannual mammograms for women aged 40 years to 49 years (Keating & Pace,
2018). In 2016, 80% of the 871 primary care physicians that were surveyed still recommended
annual screenings for women starting at age 40 years, which is contrary to the USPSTF and
American Cancer Society (ACS) guideline recommendations (Keating & Pace, 2018). A study
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showed 132 per 100,000 women were over diagnosed for cancer that would never show clinical
signs or symptoms in the women’s lifetime utilizing mammograms (Welch, Prorok, O’Malley, &
Kramer, 2016). Since many studies have linked over diagnosing breast cancer with falsepositives from mammograms, the USPSTF and the ACS have recommended the use of family
history screening tools over mammograms in young men and women (Keating & Pace, 2018).
Gornick et al. (2018) surveyed 537 newly diagnosed breast cancer patients to determine
their common knowledge regarding genetic testing. The results showed that patients’ overall
knowledge of genetic testing regarding BRCA1 and BRCA2 was low (29.8%). Gornick et al.
(2018) found that interest in genetic testing was increasing and should be discussed as an option
for screening within the primary care clinic. A recent study pointed out the clinical importance of
utilizing multi-gene testing within the primary care setting as well as the fact that genetic testing
guidelines are developing rapidly resulting in multiple revisions to genetic testing guidelines
(Beitsch et al., 2018). Furthermore, genetic testing criteria have become more complicated, yet
these criteria have not been sufficiently re-evaluated (Beitsch et al., 2018). It is estimated that 1.2
to 1.3 million women with a history of breast cancer have not undergone genetic testing despite
USPSTF and the ACS’ evidence-based practice guidelines supporting this type of testing as a
standard of care (Childers, Childers, Maggard-Gibbons, & Macinko et al., 2017). Furthermore,
over 70% of eligible patients with breast cancer have never discussed genetic testing with a
health care provider (Childers et al., 2017). There is increasing evidence, which supports the
benefits of identifying BRCA gene mutations in early breast cancer to evaluate the risk of
recurrence (Nilsson et al., 2017).
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Assessment
The clinic where the evidenced based practice project was implemented is located in the
northeast side of San Antonio, Texas. The clinic is privately owned and staffed with one
physician, one nurse practitioner, an office manager, two administrative personnel, and three
medical assistants (MA) that are bilingual in English and Spanish. Each provider typically sees
about 15 to 20 patients a day, with the majority of patients being private insurance holders.
Figure 2 provides a summary of the ethnic groups seen in the clinic and figure 3 provides a
summary of the age groups seen in the clinic. As shown, the clinic sees primarily Caucasian
patients between the ages of 45-64 years.

3%
6%

38%

Caucasian

Hispanic

53%

African American

Other

Figure 2. Ethnicity of the patient population within the clinic.
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Figure 3. Age groups of the patient population within the clinic.

This clinic did not screen for breast cancer, nor did they offer genetic testing prior to this
project intervention. During the microsystem assessment 100 patient charts were audited, which
revealed that 42% of the patients met the national recommended guidelines to be offered genetic
testing. Many organizations defer to the USPSTF guidelines, because this group of health experts
review the strength of the evidence found in the research and determine the benefits and harms
each reviewed method poses to patients (USPSTF, 2018a). The USPSTF makes
recommendations based off their reviews of the evidence to help guide healthcare providers in
managing their patients appropriately. The USPSTF national guidelines for genetic testing
recommend that patients who have had one family member diagnosed with either breast, colon,
or uterine cancer under the age of 49 years be considered to have an increased risk for potentially
harmful mutations in BRCA1 and BRCA2 (Hampel, Bennett, Buchanan, Pearlman, & Wiesner,
2015). The guidelines also state if a family member has an ovarian or pancreatic cancer at any
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age, then they too should be considered a high risk for BRCA 1 and BRCA 2 mutations and
should be offered genetic testing (Hampel et al., 2015).
Organization’s Readiness for Change
Upon review of the USPSTF guidelines and the results of the microsystem assessment it
was determined in consultation with the key stakeholders that the clinic was not aligned with the
current national guidelines. Both providers had personal experiences with cancer affecting family
members thus they were interested in learning more regarding genetic screening and testing.
Both providers were already aware that genetic testing for cancer existed, however they were
unaware of the practice guidelines that determine which patients should be screened. This
interest in practice guidelines for genetic screening and testing is what made the key stakeholders
ready to implement my project. They had expressed an interest in offering genetic screening and
testing to their patients and were aware that they needed education on the national practice
guidelines for screening.
After identifying that a problem existed in the clinic, I developed a project to implement a
process that would screen, test, and provide referrals to patients at high risk for BRCA mutations
based on the USPSTF guidelines. A short meeting was held with the office manager and each
provider individually to fully explain the project’s intent and to create a protocol that involved all
of the stakeholders. The staff and providers were able to verbalize an understanding of the
project’s purpose, objectives and interventions. The providers and staff expressed a willingness
to participate in this project implementing the evidence-based USPSTF guidelines for BRCA
testing in the clinic as a method of improving patient care for both women and men in this
patient population.
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Project Identification
Purpose and Objectives
The purpose of this project was to implement an evidence-based practiced screening
process that included genetic counseling and genetic testing for patients who were considered at
high risk for breast cancer in order to improve patient outcomes according to the USPSTF
guidelines. The USPSTF guidelines recommend screening all patients, both men and women,
and when appropriate, provide genetic testing and referral for genetic counseling to ascertain
genetic risks for gene mutations associated with breast cancer.
The objectives for this evidence-based practice project were to:
1. Increase patient screenings for risk factors associated with breast cancer from the preintervention rate of 0% to 80% by the completion of the 5th week of the project.
2. Increase the percentage of genetic testing from 0% to 80% in those patients identified
as high risk based on screening.
3. Increase the percentage of referrals for patients with genetic mutations to genetic
counseling from the pre-intervention rate of 0% to 95%.
Anticipated Outcomes
Prior to the start of my project it was anticipated that implementation of the screening
tool would result in the clinic experiencing an increased number of patients being identified as
high risk for breast cancer, thus possibly leading to genetic testing and subsequent genetic
counseling. Since I anticipated that the clinic would experience an increase in genetic screenings,
genetic testing, and genetic counseling referrals, I also predicted that the providers would be
willing to continue the implemented interventions, increasing the likelihood that the project
would be sustainable.
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Summary and Strength of Evidence
Melnyk and Fineout-Overholt’s (2015) system of grading the quality and level of
evidence was used for this project. The quality of the evidence was rated using a I-IV scale and
the level of evidence was rated using a I-VII scale. Specifics regarding the criteria that Melnyk
and Fineout-Overholt (2015) define for the numerical rating scales can be found in table 2 and
table 3, respectively.
Table 2
Quality of Evidence
Quality of Evidence

Criteria

I

Acceptable quality: No concerns

II

Limitations in quality: Minor flaw or inconsistencies
in the evidence

III

Major limitations in quality: Many flaws and
inconsistencies in the evidence

IV

Not acceptable: Major flaws in the evidence

Evidence relevant to this project was identified with a comprehensive literature search.
Searches were performed using PubMed and CINAHL. In addition, the Cochrane Library and
the National Guideline Clearinghouse databases were searched. Searches were conducted using
the key words BRCA, genetic testing, mammograms, breast cancer and cancer genes. The
reference lists in the selected articles were also reviewed for pertinent evidence. Research articles
from the primary care settings, oncology settings, as well as position statements and guidelines
from professional associations and societies were also reviewed. Based on this literature review
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15 articles were reviewed and rated.
Table 3
Level of Evidence
Level of Evidence Study Design
I

Systematic reviews and meta-analysis of randomized controlled studies

II

Randomized controlled studies

III

Non-randomized controlled studies (quasi-experimental)

IV

Case-control or cohort studies

V

Systematic reviews of qualitative or descriptive studies

VI

Qualitative or descriptive studies

VII

Opinion of authorities and/or reports of expert committees

Intensive screening for breast cancer is associated with an increase in false-positive
results, unnecessary imaging, and unneeded surgery (USPSTF, 2018b). Other studies have
confirmed that mammograms can result in higher rates of false-positives (King et al., 2014).
False positive results lead to prescribing medications such as tamoxifen and raloxefine which
increases the risk in women for thromboembolic events, cataracts and endometrial cancer (King
et al., 2014). Additionally, women identified as being at high risk for breast cancer by
mammograms have had unneeded surgeries resulting in complications such as hematomas,
contractures, numbness, pain, infection, swelling, bleeding, pulmonary embolisms, and
decreased sexual function due to changes in the body (USPSTF, 2018b).
Henderson, Hubbard, Sprague, Zhu, & Kerlikowske (2015) conducted a study that
showed women who had false-positive mammogram results that led to additional imaging and
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testing were at a higher risk of having breast cancer within the next decade. During the 10 year
follow-up of 12,022,560 people, 48,735 cancers were diagnosed (Henderson et al., 2015). When
compared to women with a true-negative examination, women with a false-positive with
additional imaging recommendation had increased risk of developing breast cancer as did
women with a false-positive with a biopsy recommendation (Henderson et al., 2015). Women
with a false-positive result had persistently increased risk of developing breast cancer 10 years
after the false-positive examination (Henderson et al., 2015). There is no definitive explanation
regarding why false-positive mammograms appear to be linked to a slightly higher risk of
invasive disease but it was hypothesized that the breast tissue changes that lead to the falsepositive mammogram result might in fact be predictive of future breast tissue changes
(Henderson et al., 2015). Many studies have concluded that subtle changes on mammograms
may be an early clue to cancer before actual cancer exists (Puliti et al., 2012). It is also important
to note that these finding has been seen in multiple studies. Studies with large sample sizes of
women and extended lengths of follow-up have contributed to more evidence linking falsepositive results with a higher risk of invasive breast cancer later in life (Puliti et al., 2012).
Approximately 67% of women 40 years of age and older have had a mammogram screening
biannually with 16% of the first mammogram and 10% of subsequent mammograms resulting in
false-positives (Henderson et al., 2015). Over a period of 10 years, the probability of having at
least one false-positive mammogram is 61% for women who were screened annually and 42%
for women who were screened biannually (Henderson et al., 2015).
These results are consistent with several studies, such as the study by Euler-Chelpin,
Risor, Thorsted, and Vejborg (2012) that found a 67% increased risk for breast cancer among
women with false-positives. Another study that was conducted over the course of 17 years found
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that false-positives from mammograms involving fine needle aspiration cytology or biopsy had a
significantly higher risk for breast cancer than women who had additional imaging procedures
alone (Castells et al., 2013). In this study, the overall cancer detection rate was 2.89 cases for
every 1,000 mammogram screenings (Castells et al., 2013). The detection rate for women with a
history of a false-positive result involving additional imaging was 4.53 per 1,000 mammogram
screenings, and those involving a fine-needle aspiration were 7.09 per 1,000 screenings (Castells
et al., 2013). The study identified other factors associated with higher detection rates including
having a first-degree family history of breast cancer (Castells et al., 2013). Additionally, a study
conducted in the United Kingdom, found that women who had a false-positive result from their
first mammogram, had a higher interval cancer rate than women with true negatives and also had
more advanced stages of cancer (McCann, Stockton, & Godward, 2002). However, as previously
mentioned, there is insufficient evidence to determine the association between false-positives and
high risks of developing cancer. This study concluded that false-positive mammographies
leading to unnecessary assessment of cancer free women has unintended associated costs
(McCann et al., 2002). First, there are psychological costs associated with the inconvenience of
the procedure and increased anxiety in women that were falsely identified (McCann et al., 2002).
Second, there are the direct financial costs associated with performing the procedures (McCann
et al., 2002).
In a nonrandomized comparison study by Riedl et al. (2015), BRCA mutation carriers
and women with a high familial risk for breast cancer were offered triple and single diagnostic
screenings with mammography, ultrasound, and magnetic resonance imaging (MRI) every 12
months. Diagnostic performance was compared between individual modalities and their
combinations. Additional comparisons included age, mutation status and breast density. There
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were 559 women with 1,365 completed imaging rounds included in this study (Riedl et al.,
2015). The sensitivity of MRI (90.0%) was significantly higher than that of mammography
(37.5%) and ultrasound (37.5%) (Riedl et al., 2015). Out of 40 cancer types, 18 were detected by
MRI alone and two cancers were found by mammography alone (Riedl et al., 2015). The triple
modality approach, which included all three diagnostics, yielded the highest detection rate, but
also had higher false-positives and costs (Riedl et al., 2015). Age, mutation status, and breast
density had no influence on the sensitivity of MRI and did not affect the superiority of MRI over
mammography and ultrasound (Riedl et al., 2015).
Current evidence suggests that genetic testing can accurately detect BRCA mutations
with little to no risk of harm associated with testing in both men and women (USPSTF, 2018).
However, consideration of screening for BRCA mutations should begin once the individual
reaches 18, the age of consent (King et al., 2014). In 1995, the American Society of Human
Genetics (ASHG) and American College of Medical Genetics and Genomics (ACMG) issued a
joint report that offered points to consider for genetic testing in children. The clinical context of
that report focused on decisions about testing for single-gene disorders in response to either a
family history or within-population screening programs (Botkin et al., 2015). The social context
of that report included limited data about the psychosocial impact of such testing in children. The
ASHG and ACMG recommended that clinicians and parents consider medical benefits related to
diagnosis, prognosis, and interventions as the best justification for testing in children (Botkin et
al., 2015). Additionally, the report acknowledged that there was limited information about risks
and benefits of genetic testing in children thus the report recommended deferral of testing due to
this uncertainty. The report has been influential in encouraging caution when testing children,
but often has been over-interpreted as a stricter prohibition of predictive testing in children for
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adult-onset conditions than was intended (Botkin et al., 2015). There has been a significant
increase in research regarding the impact of predictive testing in high-risk families since the first
ASHG ACMG pediatric testing statement, which was established over 20 years ago (Botkin et
al., 2015). To date, this limited research has not found evidence of significant psychosocial
harms in children (Botkin et al., 2015). Currently, the ASHG now offers the following
recommendations:
•

Unless there is a clinical intervention appropriate in childhood, parents should be
encouraged to defer predictive or pre-dispositional testing for adult-onset conditions until
adulthood or at least until the child is an older adolescent who can participate in decision
making in a relatively mature manner (Botkin et al., 2015).

•

Adolescents should be encouraged to defer predictive or pre-dispositional testing for
adult-onset conditions until adulthood, because of the complexity of the potential impact
of the information at formative life stages (Botkin et al., 2015).

•

Providers should offer to explore the reasons why parents or adolescents are interested in
predictive or pre-dispositional testing for adult-onset conditions. Providers can
acknowledge that, in some cases, testing might be a reasonable decision, but decisions
should follow a thorough deliberation (Botkin et al., 2015).
More than 90% of hereditary cases of breast cancer are thought to be a result of a

mutation in BRCA1 and BRCA2 (Paluch-Simon et al., 2016). A founder mutation or founder
variant is a genetic alteration observed in high frequency within a group, in which one or more of
the ancestors was a carrier of the altered gene (National Cancer Institute [NIH], 2018). Over
2,000 different mutations have been identified in BRCA1 and BRCA 2 genes with founder
mutations being the most prevalent in some populations (Paluch-Simon et al., 2016). For
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example, up to 2.5% of the general Ashkenazi Jewish population harbor a mutation in either the
BRCA1 (C.5266dupC) or BRCA2 (c.5946delT) (Paluch-Simon et al., 2016).
A recent study with a rather large sample consisting of 8,000 men studied the association
between relatives who were carriers of BRCA gene mutations. All participants were healthy,
cancer-free men that were tested for genetic BRCA1 and BRCA2 mutations. Out of the 8,000
men, 175 tested positive for having BRCA1 or BRCA2 genetic mutations (King et al., 2014).
Female relatives of the 175 men were then tested for the same gene disorders and were found to
be carriers of the same BRCA mutations, placing them at a very high risk for cancer (King et al.,
2014). The evidence supports offering genetic testing to those with personal or family history of
cancer, and to those who are relatives of confirmed carriers (King et al., 2014).
The reviewed evidence consistently agreed that genetic testing is still rather new and as
newer, more advanced equipment is developed, more research is still needed. With that being
said, much of the level I evidence recommends reviewing and revising the current genetic testing
guidelines to reflect current evidence and recent trials. Several of the level I studies support the
recommendations that mammograms should not be the sole basis of screening men and women
for breast cancer. The evidence suggests that there is a benefit of BRCA genotyping patients who
are newly diagnosed with breast cancer and recommends genetically testing men and women for
mutations that suggest an increase likelihood of developing cancer allowing for early
implementation of preventive measures.
Nelson et al. (2013) reviewed 70 studies evaluating the evidence on the benefits and
harms of risks assessments, genetic counseling and genetic testing. Results showed those who
received counseling post genetic testing experienced less depression and worry regarding both
low and high-risk genetic results (Nelson et al., 2013). Although evidence such as this suggesting
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that offering genetic counseling with genetic testing reduces depression and anxiety, recent
studies have shown that providers are not adhering to these recommendations (Armstrong et al.,
2015). A study by Armstrong et al. (2015) identified factors associated with use of BRCA testing
to assess whether delivery of genetic counseling and testing services was adhered to as part of
the professional guidelines and measures the impact on patient-reported outcomes. This study
analyzed data from providers throughout the United States and collected data from 11,159
women whose provider ordered BRCA testing between December 2011 and December 2012.
Findings revealed that only 1,334 (36.8%) women received genetic counseling prior to genetic
testing with the lowest rates 130 (12.3%) among patients of obstetricians and gynecologists
(Armstrong et al., 2015). The most commonly reported patient reason for not receiving
counseling was due to lack of provider recommendation (Armstrong et al., 2015). This study also
concluded that the patients that did receive genetic counseling demonstrated greater knowledge
about BRCA mutations, greater understanding of the genetic information, and expressed greater
satisfaction (Armstrong et al., 2015).
During the review of the evidence, it is apparent that there is very little research
concerning breast cancer in men. It is under acknowledged clinically and socially as a real risk to
men’s health, even though breast cancer in men persists as a critical health issue with complex
ramifications for those affected (Sirieix et al., 2018). Breast cancer in men accounts for 1% of all
breast cancer and management is still largely based on breast cancer management in women
(Sirieix et al., 2018). Only a small amount of retrospective series on metastatic cases have been
reported so far (Sirieix et al., 2018). Currently there is a multi-center project that aims to collect
data from clinical trials and comprehensive cancer centers to improve the customized
management of breast cancer in men. So far, the only conclusive finding is that compared to
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women, the prognosis and treatment effects for male breast cancer are the same (Sirieix et al.,
2018). Unfortunately, studies examining male breast cancer are not routinely funded (Sirieix et
al., 2018). Recently the National Comprehensive Cancer Network (NCCN) (2019) started
recommending that men age 35 years or older start performing self-breast exams and have an
annual breast exam performed by providers. It is evident, that more research is needed to be able
to offer early preventive measure to both men and women and if necessary, early interventions to
reduce morbidity and mortality rates for these patients.
Methods
Project Intervention
Prior to implementation of this project several meetings were held with the clinic
providers and staff based on their roles in implementing the project. A demonstrational meeting
was held for the front desk personnel and MAs to allow them to visualize the workflow of the
intervention and to ask questions about the implementation process. Another meeting was held
on the same day with the laboratory technician to verify that she understood all of the
components in the genetic testing kit that needed to be completed in order to process patient
samples. The laboratory kit contained one lavender tube and a consent form (see appendix B).
The laboratory technician completed a successful return demonstration of how to process the
genetic kits. The laboratory technician was familiar with the genetic kit as she had previously
processed some samples the previous year. A final meeting was held with both providers to
explain the workflow of the intervention and to identify possible barriers to implementation.
Starting on day 1 of implementation, each patient 18 years of age and older entering the
clinic was given an electronic tablet issued by the clinic’s genetic lab company of choice, Myriad
Genetics, which contained an electronic hereditary cancer risk survey. Myriad Genetics was the
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clinic’s preference because this company currently offered a 35-gene panel (see appendix C) that
tests for nine types of cancers and 11 genes (see appendix D) that are not only specific to breast
cancer, but also to ovarian cancer, melanoma, pancreatic cancer and prostate cancer. This was
important for the clinic because the results of a recent study showed that those identified with
BRCA1 mutations had a higher incidence of breast cancer, ovarian cancer and melanoma
(Mersch et al., 2015). This same study showed that BRCA2 mutations were reported to increase
the risk of developing pancreatic cancer and prostate cancer (Mersch et al., 2015). The electronic
tablets containing the online screening survey were handed to the patients during check in by the
front desk receptionist and patients were asked to complete the screening survey. Once the
electronic tablet screening survey was completed, the tablet was handed back to the front desk
receptionist. The electronic tablet screening survey, MyRisk Screening Survey, is an online
screening tool by Myriad Genetics that utilizes the USPSTF and the NCCN national clinical
guidelines for screening tools in genetic testing. The MyRisk Screening Survey incorporates the
national clinical guideline which state if the patient has one family member diagnosed with either
breast cancer, colon cancer, or uterine cancer under the age of 49 years, then they should be
deemed as having an increased risk for potentially harmful mutations in breast cancer
susceptibility genes (Hampel, Bennett, Buchanan, Pearlman, & Wiesner, 2015). Another
consider is if a family member has had ovarian cancer or pancreatic cancer at any age, then they
too should be deemed as having an increased risk for mutations in the BRCA1 and BRCA2
genes (Hampel et al., 2015). All patients meeting any of these criteria should be offered genetic
testing to be in compliance with current national clinical guidelines.
Once the electronic screening survey was completed, a risk score was generated
recommending either performing genetic testing (see appendix E) or not performing genetic
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testing (see appendix F). The receptionist would then print out and attach the risk score report to
the patient’s chart, and the MAs would place the entire chart outside the patient’s room for the
providers as per their usual protocols. The only difference was the charts now contained the
patients’ risk score reports. The providers reviewed the risk score reports and explained
recommendations for genetic testing along with the pros and cons of genetic testing. The
providers were educated about the USPSTF national guidelines recommending offering genetic
counseling prior to testing, but both providers declined this part of the intervention. The
providers stated that insurance companies would not pay for genetic counseling prior to genetic
testing. Instead, the providers performed basic genetic counseling themselves to educate the
patients about genetic testing discussing the fact that genetic testing does not detect cancer, but
rather determines the genetic risk of developing cancer based on any mutations in genes. If
patients were screened as high risk, the providers would encourage genetic testing to be
performed. If a patient agreed to genetic testing, the providers would review the consent form
supplied in the testing kits with the patient and a signature was obtained consenting to the
testing.
Once the consent form was signed, the provider would walk the patient to the in-house
laboratory to have their blood drawn by the laboratory technician using a lavender tube. The
laboratory technician would then place the specimen in a pre-posted package setting it aside for
pick up by FedEx. Once the genetic company received the specimen, the company would contact
the patient’s insurance and determine if the genetic testing would be covered. All genetic testing
was reported as being covered so no missed opportunities occurred for this reason. The average
turn-around time to receive results was approximately 10 to 14 business days. Each provider
would receive a notification via email informing them that results had been uploaded into the
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database and were ready for viewing. Results indicated the inherited genetic risk of developing
cancer. Based on the presence of mutated genes, a report was generated that provided a
percentage risk of developing breast cancer within 5 years and a percentage risk of developing
cancer over one’s lifetime (see appendix G). For example, results associated with a high-risk
patient may state that the patient has a 38% chance of developing breast cancer within 5 years
and a 60% chance of developing breast cancer over the course of the patient’s lifetime. Results
could also indicate that a patient was at low risk for developing breast cancer if no signs of
genetic mutations existed for any of the breast cancer genes (see appendix H), in which case the
provider would inform the patients of the results over the telephone. Patient’s that had genetic
mutations were scheduled by the front desk receptionists to be seen in the clinic to discuss the
results and were then educated by the provider on preventive measures and lifestyle
modifications such as quitting smoking, exercising regularly, and increasing foods associated
with higher levels of antioxidants to reduce their chances of developing breast cancer (American
Cancer Society, 2018). The providers also educated the patients about additional and alternative
screening measures. These recommendations included those listed by the USPSTF (2018b) for
BRCA mutation carriers to reduce risk for cancer or cancer related deaths such as intensive
cancer screening, risk reducing medications, and risk reducing surgeries. Medications such as
tamoxifen and raloxifene have been shown to reduce the incidence of invasive breast cancer in
high risk women, but have not been studied in men (USPSTF, 2018b). The patients were also
educated that risk reducing surgeries such as mastectomy and salpingooophorectomy
significantly reduce the risk of developing breast cancer (USPSTF, 2018b). The USPSTF
(2018b) also recommends women who have been genetically identified as being high risk for
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developing breast cancer to start receiving mammograms twice annually and if currently only
receiving mammograms annually, then switching to screening twice a year.
After the primary care providers discussed the results and recommendations with the
patient, the providers offered a referral to one of the local genetic counselors based on the
patient’s insurance coverage. A referral to a geneticist counselor was recommended to reduce the
incidence of the patient developing anxiety or depression due to having received results (Nelson
et al., 2013). If the patient agreed to attend genetic counseling, the receptionist would submit the
referral. The patients who had declined a genetic counseling referral only received the basic
recommendations from the provider that was previously mentioned. There were no incidences
where the insurance did not cover the genetic counseling and there were no patients who
declined a referral based on their personal insurance coverage.
Organization Barriers and Facilitators
Barriers. The organization experienced a few barriers to implementing the interventions
as planned. These barriers included failure to screen all patients 18 years and older, loss of wi-fi
connectivity and software updates required with the electronic tablets, patients not understanding
how to use the tablets as well as patients not willing to participate after receiving the patient
education.
Initially the front desk receptionists kept forgetting to hand out an electronic tablet to
each patient who was 18 years of age and older. However, after another meeting with the front
desk receptionists to re-educate the importance of the screenings, they were more consistent with
screening every eligible patient by week 2.
At times the electronic tablets would have some connectivity issues, or the electronic
tablet software needed to be updated. The front office receptionists attempted to reset the
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electronic tablets to correct these issues, but if this intervention did not correct the problem, no
other attempts were made. These electronic tablets were not available to use until I fixed the
issues, which resulted in multiple missed opportunities between week 1 and week 3.
The most significant barrier occurred with elderly patients who did not know how to use
the electronic tablet or did not understand the survey questions. This required the front desk
receptionists to assist these patients in completing the survey as they were the first person
available to the patients. During the pre-intervention stage of the project, the receptionists were
asked to complete the survey so they would have a good understanding of how it worked, what
to expect and how to answer certain screening questions should the patients have any questions.
The front office receptionists successfully assisted each patient that required assistance, thus no
missed opportunities were attributed to this barrier.
However, there were many misconceptions among the patients regarding the screening
and the testing that may have altered their decision to participate in the project. Some common
misconceptions verbalized by the patients included:
•

“I don’t have any kids, so it doesn’t matter.”

•

“There is nothing I can do if I have the mutated gene.”

•

“I get mammograms, so I don’t need to get tested.”

•

“I probably wouldn’t have to worry either way since I’m a male.”

•

“I’m too old to have to worry about genetic testing for breast cancer.”
Facilitators. Facilitators to implementing the project interventions included staff

familiarity with BRCA genetic testing, the clinic’s affiliation with a genetic laboratory company,
patients’ willingness to participate in the project, and staff familiarity with processing the
laboratory kits and consent forms.
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The clinic’s nurse practitioner was familiar with the genetic testing process since she had
previously processed a few patients for genetic testing in 2017. However, these patients were not
screened or tested accordingly to any guideline and were only tested due to the patient’s own
concerns of having breast cancer. Both providers were already familiar with the genetic
laboratory company’s processes and already had the lab kits needed for blood draws in storage.
The laboratory technician was also familiar with obtaining the specimens since she was the one
who performed the testing in 2017. The clinic had a previous affiliation with the genetic
laboratory company used for this project because this company processed the genetic tests in
2017. As a result of already having an affiliation in place, the genetic company provided the
electronic tablets and laboratory kits to the clinic at no cost.
Patients were also facilitators to this project, as the majority of eligible patients were
interested in completing the electronic tablet screening survey. Some of the reasons that patients
participated in the project were patients possessing personal knowledge about genetic testing,
curiosity and interest about genetic testing, personal predispositions that motivated patients to
have genetic testing done, and some patients having friends or family that received genetic
testing and recommended the screening to the patient.
Ethical Considerations
As with any project, it is important to consider ethical considerations. When researching
similar studies, no one reported patients experiencing any harm from participating in a cancer
risk assessment (Moyer, 2014). However, as previously mentioned prior studies have shown an
increased in anxiety and depression after meeting criteria for genetic testing or after receiving
results. By the same token, other studies have reported a decrease in anxiety, depression, worry
and an increase in the accuracy of risk perception after counseling (Moyer, 2014). After
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disclosing this information to the providers, an agreement was reached that the providers would
provide the initial genetic education themselves because they felt that an initial genetic
counseling session would not be covered by insurance prior to testing. However, both providers
agreed that a post genetic testing referral would be implemented into the project interventions.
According to the American College of Obstetricians and Gynecologists (ACOG) (2014),
another ethical dilemma that should be considered is having a formal consent, which explains
that genetic testing may have important consequences or require difficult choices. For example,
patients should be informed that the test might reveal that they have, are at risk for, or are a
carrier of a specific disease (ACOG, 2014). The results of genetic testing may require difficult
decisions to be made regarding current or future health choices, insurance coverage, career,
marriage, or reproductive options (ACOG, 2014). The providers provided a consent form to
every patient who agreed to genetic testing. The consent form included information regarding the
purpose of testing, the testing procedure, as well as the risks, benefits and limitations of genetic
testing. Also included in the consent form was a description about how test result findings are
reported and what these descriptions mean. The descriptions were defined as:
•

Positive: A mutation that is associated with an increased risk for hereditary cancer was
identified.

•

Negative: A mutation was not identified in any of the genes included as a part of your
testing.

•

Uncertain: A genetic change was detected but it is not known if this change is linked to
cancer risk.

The full consent form can be found in appendix B.
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A provider ethical dilemma is the inability of the providers to warn the at-risk relatives of
the genetic mutations. Genetic testing is absolutely confidential. Although the provider may
inform the patient of familial implications for at-risk relatives, confidentiality and federal laws
restrict providers from disclosing any genetic information to relatives without consent of the
patient (Knoppers et al., 1998). It is important that consents for genetic testing provide a warning
to patients that they may be faced with this dilemma and they should consider having genetic
counseling prior to testing (ACOG, 2014).
This project was referred to the University of The Incarnate Word Institutional Review
Board (IRB) for review and was deemed not regulated research. Authorization (NRR [19-037])
was given to proceed with the project since it did not require IRB approval.
Results
This project lasted 5 weeks, with 154 of 329 eligible patients being approached for
screening using the electronic screening survey. Out of the 154 eligible patients that were asked
to complete the electronic screening survey, 129 (40%) of them completed it. Twenty-five (19%)
of the 129 patients screened had positive screens that resulted in a recommendation for genetic
testing based on their family and personal history. Fourteen (56%) of the 25 patients chose to
have genetic testing done. Figure 4 shows the patients who had positive high risks screens
recommending genetic testing per each week and Figure 5 shows the patients that proceeded
with genetic testing each week.
Three women (21.4%) who consented for genetic testing were identified as having a high
risk of developing breast cancer. One female patient was identified as having a clinically
significant mutation in the BRCA1 gene. This patient had an estimated 46% - 87% risk of getting
breast cancer by the age of 70 years, whereas the general population for her age group only had a
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Figure 5. Patients who received genetic testing.

7% risk. The second female patient was identified as having a 35% remaining lifetime risk based
on her family history. The third female patient was found to have had a mutated gene, with
uncertain clinical significance due to insufficient data to determine if the variant was linked to an
increased risk for any type of cancer. Myriad’s genetic protocol for this type of finding is to
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follow up with the patient if and when new research studies identify any new additional
information regarding the uncertain mutations.
Since the implementation of the project, all three (100%) patients with confirmed high
risks have been referred to genetic counseling. As of to date, one followed up with the genetics
counselor to review her results.
The number of genetic testing opportunities offered by each provider varied significantly.
Provider one explained that she had a family history of cancer and felt it was important to offer
this service to all patients. Provider two also expressed the importance of genetic testing, but he
did not want to make the patients feel pressured into getting genetic testing. Table 4 shows the
overall weekly screening rates for the clinic whereas table 5 shows the weekly testing rates by
each provider. Table 6 shows the comparison between the pre-intervention rates for each project
objective and the post-intervention rates for each project objective.

Table 4
Weekly Screening Rate
Screenings

Denied Screenings

Week 1

19

8

Week 2

15

3

Week 3

7

10

Week 4

24

3

Week 5

64

1
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Table 5
Weekly Genetic Testing Rate by Provider
Provider 1

Provider 2

Week 1

4

0

Week 2

2

1

Week 3

0

0

Week 4

3

0

Week 5

3

2

Table 6
Objective Comparisons

Patient Screening
Genetic Testing
Genetic Counseling

Objective

Pre-Intervention

Post-Intervention Objective

Goal

Rate

Rate

Met

80%

0%

40%

Not met

80%

0%

56%

Not met

95%

0%

100%

Met
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Discussion
The electronic hereditary cancer risk survey was not given consistently to patients for the
first four weeks of implementation. Due to some of the barriers mentioned such as losing wi-fi
connectivity, electronic tablets in need of software updates, and patients’ lack of willingness to
participate, the clinic was unable to maximize the number of patients screened. On several
occasions, I would sit with the front desk receptionists to review the project and interventions
clarifying any questions they had. During these times I would also review functionality of the
electronic tablets to teach the front desk receptionists how to fix some basic errors such as
resetting the wi-fi, restarting the tablet and downloading software. By frequently visiting with the
front desk receptionists, they became more familiar with the project, and operating the electronic
tablets as well as learning the impact the project has for the clinic’s patients. This resulted in
more efficiency and consistency in the last two weeks of the project.
Analysis of the data revealed no significant similarities among the three women who
were found to have genetic mutations of BRCA1 or BRCA2. Table 7 highlights patient
demographics and reproductive history of the three women who tested positive for genetic
mutations of the BRCA1/BRCA2 genes.
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Table 7
Comparison of Patients Identified with BRCA Gene Mutations
Age of Menarche

Age at First Live Birth

Hormone Replacement

Race

Therapy
Patient 1
Patient 2
Patient 3

13

21

No

Caucasian

12

25

Yes

Hispanic

15

21

No

Caucasian

These results differ from larger sample size studies that revealed that BRCA mutation
prevalence differed in women diagnosed with breast cancer based on ethnicity and race (Greenup
et al., 2013). Figure 6 shows the BRCA mutation prevalence rates by ethnicity as identified by
Greenup et al. (2013). This differs from findings from this project, which revealed a more
homogenous distribution of patients who had a higher risk of breast cancer based on the
electronic screening. Table 7 shows the ethnicity of the 14 women who had genetic testing done
based on the initial screening in the clinic. The difference in distribution may be attributed to the
fact the primary ethnicity of this clinic’s patient population was Caucasian.
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Figure 6. BRCA mutation prevalence by ethnicity.

In the study by King et al. (2014), the evidence supports offering genetic testing to those with
personal or family history of cancer and to those who are relatives of confirmed carriers. Results
from this project revealed three out of 14 (21%) patients with a family history of cancer had an
increased risk for developing breast cancer. King et al. (2014), found that the combined risk of
developing either breast or ovarian cancer was 60% (±7%) by age 60 years and 83% (±7%) by
age 80 years in BRCA1 mutation carriers. For BRCA2 mutation carriers the risk was 33% (±9%)
by age 60 years and 76% (±13%) by age 80 years (King et al., 2014). All three women in this
project identified as having a high risk for developing breast cancer were 50 years of age or
older. The one patient that had a BRCA1 significant gene mutation was 65 years of age. The two
patients who had a high risk for developing breast cancer that were in their 50’s differ from King
et al.’s (2014) findings whereas the one 65-year-old patient with the BRCA 1 significant gene
mutation is consistent with King et al.’s (2014) findings.
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Figure 7. Clinic ethnicity of women complete genetic testing.

The summary of evidence provided plenty of evidence that genetic counseling is a benefit
to patients who are receiving genetic counseling as it decreases anxiety and depression and
increases understanding of genetic testing results. Unfortunately, the evidence also revealed that
providers are not routinely adhering to this recommendation (Armstrong et al., 2015). This was
similar to findings from this project, as both providers declined offering genetic counseling prior
to genetic testing based on patient cost concerns. They did however adhere to the USPSTF’s
(2018a) recommendations of referring patients to a geneticist counselor following genetic
testing. Armstrong et al. (2015) identified that out of the 11,159 patients who received genetic
testing, only 1,334 (36.8%) women received genetic counseling prior to genetic testing.
Interestingly enough, this project found that one of the reasons for the lack of pre-genetic testing
referrals was due to lack of provider recommendations which is consistent with findings by
Armstrong et al. (2015).
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A study conducted by Struewing et al. (1997) found that the NCCN guidelines at the time
regarding genetic testing under identified patients with BRCA1/BRCA2 genetic mutations. The
study randomly selected 1,000 volunteers who had completed a family history survey and
provided a blood sample with permission to analyze it for mutations in the BRCA1 and BRCA2
genes. Out of the 1,000 men and women tested, 120 participants were found to have BRCA gene
mutations (Struewing et al., 1997). Of the 120 participants who carried a BRCA gene mutation,
31 did not report a family history of breast or ovarian cancer among first- or second-degree
relatives (Struewing et al., 1997). This led to a recommendation to revise guidelines for breast
cancer screening to include additional familial history such as the ones used for this project’s
interventions. It is interesting to note that few changes have been made to the genetic screening
recommendations from the NCCN over the past 20 years. When comparing this project’s results
with other studies such as Struewing et al. (1997) and Beitsch et al. (2018), the similarities in
results are interesting. Table 8 provides a side-by-side comparison of this project’s results with
these two studies.

Table 8
Results Comparison of Patients Identified with Having BRCA Gene Mutations
Studies

Sample Size

Results

This project

14

7%

Struewing et al. (1997) 1000

12%

Beitsch et al. (2018)

9%

959
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Factors that may have influenced the findings from this project that prevent any
assumptions being made about these similarities include the small size of this project’s
population as well as the homogeneity of the clinic’s population and the type of insurance of the
clinic patients. No men agreed to participate in genetic screening for this project. Therefore it is
difficult to know whether any correlation exists between personal and family history of cancer
and genetic mutations in the BRCA1/BRCA2 genes. Furthermore, the majority of patients in this
clinic population are private pay patients or commercial health insurance, which provides these
patients preventive health care resources that would be unavailable to underinsured or uninsured
patients. The dichotomous distribution of patients in the clinic (Hispanic and Caucasian) may
have also contributed to findings from the electronic risk screening survey and genetic testing
results. Many researchers used a more homogenous population of Ashkenazi Jewish people
when analyzing BRCA gene mutations since there is a much higher than average risk for
developing breast cancer in this population as stated in the following articles, King et al. (2014),
Walsh et al. (2017), and Struewing et al. (1997). Further research regarding the influence of
gender and ethnicity on BRCA1/BRCA2 mutations is needed.
Limitations
There were several issues with the electronic tablets during the initial implementation of
the electronic risk screening survey as previously discussed which may have affected the overall
screening, testing and referral rates. Out of 329 eligible patients that presented to the clinic
during the implementation period, only 154 (46.8%) of the patients were asked to complete the
electronic risk screening survey. Failure to ask the remaining 175 (53.2%) patients most likely
affected the genetic testing rates and subsequently the ability of the clinic to identify patients
with BRCA gene mutations.
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Additional limitations included the one provider who was not as assertive in
recommending genetic screening as the other provider. Personal bias regarding genetic testing
influenced both providers participation in the project. This most likely affected the testing rates.
The number of weeks allotted for this project intervention may have also affected the results,
since the intervention was not operational as intended until the last week.
Recommendations
The clinic has continued with the intervention of utilizing the electronic tablet screening
surveys. The nurse practitioner provider informed me that she has continued testing patients and
following up with a referral to a geneticist counselor. However, the physician provider has
completely stopped screening all patients for breast cancer using the project implementation
plan. The nurse practitioner provider verbalized that she would speak with the physician to
recommend continuing the intervention. With only one provider participating in the project plan,
approximately 50% of the clinic’s patients that are 18 years and older will be screened. I would
recommend that the front desk receptionists continue distributing the tablets to patients who are
18 years and older when they check in to the clinic. This seemed to be the most time efficient
workflow for the clinic personnel and the patients. I would also recommend the clinic getting
additional tablets from the genetic testing company in order to help increase the number of
screenings that can be completed when an electronic tablet experiences loss wi-fi connectivity or
needs software updates. The nurse practitioner provider of this clinic believes that the number of
BRCA gene mutations is significant when considering the number of patients participating in the
project. This has resulted in the nurse practitioner provider continuing the project interventions.
Perhaps with time and continued implementation of the project the physician provider may
decide to reinstate the project interventions into his practice.
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Implications for Practice
In 2018, there were no patients identified as being at high risk for breast cancer in this
clinic's population since no type of breast cancer screening was being implemented. As a result,
there were also no referrals to genetic counseling in 2018. As of to date since the implementation
of this project, three (21.4%) patients of the 14 tested have been identified as having a high risk
of developing breast cancer, and all three women were referred to a geneticist counselor. One of
these women was confirmed as having a clinically significant BRCA1 gene mutation; another
one of the women had a mutated gene with unknown clinical significance; and the third women
was found to have no mutated genes but was still identified as having a very high risk for breast
cancer due to familial history. Implementation of this project also resulted in informing 101
(78%) patients that they were at very low risk of developing breast cancer.
The results of this quality improvement project demonstrate that screening for genetic
risks aids in identifying those individuals at high risk for developing breast cancer thereby
encouraging clinicians to develop plans of care that can help minimize these genetic
predispositions for breast cancer and increase surveillance for breast cancer in these patients.
Although the project was implemented in a primary care clinic, a similar protocol would be
suitable for other specialty clinics such as an obstetrics or gynecology clinic since BRCA gene
mutations also predispose patients to ovarian cancer. Using a modified version of this protocol in
primary care or urology could also identify men with BRCA genetic mutations that not only
predispose them to developing breast cancer but also increases their risk of developing prostate
cancer. Genetic screening protocols could even be implemented in an oncology setting, as it is
recommended that patients get genetic testing done at time of diagnoses (Childers et al., 2017).

GENETIC SCREENING FOR BREAST CANCER

45

There are numerous hereditary genetic screening tools available for screening for breast
cancer risks. Some that have been recommended by the USPSTF include the Ontario Family
History Assessment Tool, Manchester Scoring System, Referral Screening Tool, Pedigree
Assessment Tool and the FHS-7 model (USPSTF, 2018). These screening tools are free for
providers to use thus providing clinics with a cost-effective method to screen for cancer causing
genetic mutations.
Implementation of this project has helped a patient to identify the specific gene that has
contributed to so many deaths in her family. This has allowed the patient to inform her siblings,
children, nieces and nephews about the specific gene mutation that runs in their family.
Knowing what gene mutations a patient has allows for specific testing, which is ultimately less
expensive, and can bring peace of mind to family members once the genetic mutation is ruled out
(D’Andrea et al., 2016). More importantly, the patient’s insurance will now cover biannual
mammograms instead of limiting the patient to an annual mammogram.
Conclusion
Healthcare providers have the ability to utilize clinical practice guidelines to potentially
have a significant impact on their patient populations. Operationalization of a genetic
screening/testing protocol similar to this one can aid providers in potentially saving lives of
patients who would otherwise have no idea that they are at high risk for breast cancer. The
importance of identifying inherited genetic mutations extends beyond the initial treatment period.
It allows providers to develop treatment plans that include prevention measures that can help
negate these genetic mutations and increase surveillance of those patients that test positive as
well as informing other family members of their risk.
.
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Force (2018b).
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King, M. C., Levy-Lahad, E.,
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with breast, ovarian, tubal, or
peritoneal cancer with one of
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and early intervention for
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mutations are small to moderate.
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recognizes that clinical decisions
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evidence alone. Clinicians should
understand the evidence but
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to the evidence of clinical benefits
and harms.
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adequate evidence that the overall
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correlation of genetic mutations in
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genetic mutations.
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screening of women for BRCA1
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routine part of clinical practice.
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cancer associated Sample: 140,387 have increased cancers and larger
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whether it extends
Implications: A possible
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at rescreening and
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determine whether
false-positive mammography might
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between women
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not experienced
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Riedl, C. C., Nikolaus, L.,
Purpose: To
Design: NonFindings: MRI allows early
Bernhart, C., Weber, M.,
evaluate the breast randomized study detection of familial type breast
Bernathova, M., Tea, M.M,… cancer screening
cancer regardless of patient age,
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efficacy of
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Design: N/A,
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I
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when genetically testing children.
Mclnerney, D. J. (2015).
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Purpose

Sample: N/A

Implications: Providers should
offer to explore the reasons why
parents or adolescents are
interested in predictive or predispositional testing for adult-onset
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parents.
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Design: N/A
Establishes clinical Clinical Practice
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evidence on the
benefits and harms
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counseling and
genetic testing for
BRCA.

Design:
Systematic
reviews of
randomized
studies

FIndings/Implications
Findings: Follow-up counseling
outlining options for screening for
early detection, risk-reducing
measures and issues pertaining to
fertility in women who have not
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fundamental.
Implications: If available, genetic
mutation carriers should be
encouraged to participate in
dedicated high-risk follow-up
clinics that specifically focus on
follow-up and screening of
individuals with a known
hereditary cancer syndrome.
Findings: Genetic counseling
decreases anxiety and depression
regarding cancer and improves
understanding of genetic testing
results.

Sample: 70 studies Implications: No trials evaluated
the effectives of intensive
screening or risk reducing
medications in genetic mutation
carriers, although false positive
rates, unneeded imaging, and
unneeded surgeries were higher
with screening.
Armstrong, J., Toscano, M.,
Purpose: To
Design:
Findings: Despite improved patient
Kotchko, N., Friedman, S.,
identify factors
Systematic review knowledge, understanding, and
Schwartz, M. D., Virgo, K,... associated with use of qualitative and satisfaction among patients who
Sutphen, R. (2015).
of BRCA testing to descriptive studies receive genetic counseling by a
assess whether
genetics clinician, as well as
delivery of genetic
multiple guidelines emphasizing
Sample: 11,159
counseling and
the importance of genetic
testing services
counseling, most U.S. women
adheres to
undergoing BRCA genetic testing
professional
do not receive this counseling
guidelines and
service. Lack of physician
measure the impact
recommendation is the most
on patient-reported
commonly reported reason.
outcomes.
Implications: This finding
demonstrates the important gaps in
clinical genetic services. Mandated
coverage of genetic counseling
services as a preventive service
without patient cost sharing should
contribute to improving clinical
genetics services and associated
outcomes in the future.
Siriex, J., Fraisse, J.,
Purpose: Providing Design:
Findings: Men who received
Mathoulin-Pelissier, S.,
a large
Randomized
hormonal therapy when compared
control study.
Leheurteur, M., Vanlemmens, comprehensive
to a matched cohort of women
L., Jouannaud, C.,... Frenel, J. analysis of
showed slightly higher survival
S. (2018).
metastatic breast
rates from breast cancer.
Sample: 16,701
cancer in men.
Implications: More biological
information is needed to improve
the customized management of
metastatic breast cancer in men.
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National Comprehensive
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(2019).
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Design/Sample FIndings/Implications
Setting
Purpose: To update N/A Clinical
Findings: Recommends that men
clinical practice
Practice Guideline. age 35 years or older start
guidelines for
performing self-breast exams and
breast cancer
have an annual breast exam
screening in men.
performed by providers.
Purpose
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